Genetic mutation of PLOD1/2/3 was present in ~3% of ccRCC patients and was associated with significantly poorer prognosis compared with expression of wild-type PLOD1/2/3 (p<0.001). The gene discussed is PLOD1; the disease is nonpapillary renal cell carcinoma.